Access Biotechnology
Access Biotechnology is an investment arm of Access Industries that focuses on private and public biopharma companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Access Biotechnology Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – from discovery-stage technology platforms to late-stage clinical programs. The company is based in New York.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2021 | Eliem Therapeutics | Series B | 0 |
| 6/2022 | Upstream Bio | Series A | 200M |
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 7/2021 | Nimbus Therapeutics | Private Equity Round | 105M |
| 11/2021 | Matchpoint Therapeutics | Seed | 30M |
| 10/2019 | Disc Medicine | Series A | 50M |
| 3/2021 | Eliem Therapeutics | Series A | 80M |
| 9/2022 | Nimbus Therapeutics | Venture Round | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 11/2021 | Recludix Pharma | Series A | 60M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2023 | Hemab | Series B | 0 |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 9/2022 | ACELYRIN | Series C | 0 |
| 6/2023 | Upstream Bio | Series B | 0 |
| 12/2021 | Curie Therapeutics | Series A | 75M |
| 3/2021 | DTx Pharma | Series B | 100M |
| 2/2023 | Hemab | Series B | 0 |
| 9/2022 | ACELYRIN | Series C | 0 |
| 9/2022 | Nimbus Therapeutics | Venture Round | 0 |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 6/2022 | Upstream Bio | Series A | 0 |
| 12/2021 | Curie Therapeutics | Series A | 0 |
| 11/2021 | Recludix Pharma | Series A | 0 |
| 11/2021 | Matchpoint Therapeutics | Seed Round | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
